143 related articles for article (PubMed ID: 37263397)
1. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract][Full Text] [Related]
2. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
4. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
8. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
9. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
10. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
[TBL] [Abstract][Full Text] [Related]
13. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
[TBL] [Abstract][Full Text] [Related]
15. Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.
Izarn F; Allignet B; Gille R; Boyle H; Neidhardt EM; Négrier S; Fléchon A
Clin Genitourin Cancer; 2023 Apr; 21(2):e35-e43. PubMed ID: 36272959
[TBL] [Abstract][Full Text] [Related]
16. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.
Naik P; Dudipala H; Chen YW; Rose B; Bagrodia A; McKay RR
Ther Adv Urol; 2024; 16():17562872241232578. PubMed ID: 38434237
[TBL] [Abstract][Full Text] [Related]
17. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
19. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
20. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
